Downloaded from irje.tums.ac.ir at 16:09 IRDT on Sunday April 21st 2019

Transcription

1 .-9 : : : :. : p.yavari-grc@sbmu.ac.ir: 92/3/4 : 9//24 : - (CANMOD) : : /7 75/4 :..(2 3) (DALY).(4). ٢(YLL) Disability Adjusted Life Years 2 Years of Life Lost due to premature death. :.().

2 / ( /) ( /7) ( ) () (YLD) DALY.(5 6) ( ). 28 6/3 8/7. 4/6 6/4 6/7 %7.(7).(8) (9) (). 387 : Years Lived with Disability

3 3/ 387..(4).6.( 5-3) (5). (expert panel ) 5 %39 %45 (5-22) %54 % 87 3 (5-3) %95 4 (23-28) 8 (29-3) 2 (6-8). (Can Mod) ( ) (3) YLD. YLL (DALY)..(3 5) 26 Coal and Demney 82/5 ) 8. (32) (. 3.5.(2).4. ) 2 Can Mod (.. (3 3)...(3 3). Misclassification 2 Cancer Modeling software

4 /4 DW I ) L r /4 ( c a /3. /658. (33) 3/7 72/3 79/6 86/ /9 237/6 539/5 76/8 66/6 98/9 3376/9 682/5 2238/6 433/9 2 (3 3). : (YLL) L N a /3 r /4 c. /658 :2 (YLD) - - ) ( / /3 /96 2/ 2/9 8/4 7/88 2/23 22/9 26/67 26/67 3/83 37/2 29/6 4/3 / /55 /78 3/7 5/33 4/59 32/73 36/86 4/4 48/44 56/2 67/8 53/89 7/ / 77/9 74/6 23/6 252/3 387/8 542/7 726/5 67/8 724/9 3497/ 485/2 732/4 774/8 629/3 YLL=N Ce (ra / (β+r) 2 [e ( β + r) (L+a) [-(β+r) (L+a)-]- e ( β + r)a [ (β+ r)a-]] YLD=I DW Ce (ra) /( β+r) 2 [e ( β +r)(l+a)[-(β+ r)(l+a)-]- e ( β + r)a [ ) ( / /48 /2 /97 3/65 5/72 9/48 4/6 23/99 28/93 3/23 44/86 52/2 29/25 5/5 /22 /8 /69 3/26 6/5 9/44 5/69 24/7 39/44 48/4 52/8 74/24 84/69 48/5 9/ <

5 5/ (DALY) 2/8 7/5 89/9 25/5 295/6 26/7 87/ 72/ (DALY) 2/3 4/6 83/5 25/6 273/3 226/8 93/2 66/7 3/3 2/2 95/4 249/6 35/ 288/8 83/7 76/6 ٢/١ 3/3 75/ 222/3 235/7 86/8 66/ 58/7 (YLL) 3/ 8/6 86/5 222/4 272/4 237/ 59/6 67/7 / /3 8/4 29/3 37/6 4/ 27/ 8 (YLD) /2 /6 8/9 27/2 42/6 5/7 24/ 8/ (DALY) (DALY) (YLL) (YLD) ( 4/3) ) ( () /7 67/7 8 8/ / ( 3533) 56/9. ( 2676) ( 7/9) ( 9/) ( 5/5) CanMod

6 /6. /7 (7) (2 3 ). (/3 /4 ).(4 5) ( 72) /4) 382.(3) (.(33) : ( (33) ( (34) (34) (2 ) (YLL). (YLD).(3 ) 6 3 CanMod. ( ).( ) ( ) 29928) ( 2266) 43 ( ( 52534) DALY ( 692) YLD 2. DALY YLD.(7 3)

7 7/ ( ).. (.(35 36) ( (BMI).(9) (. : (co-morbidity) World Health Organization, How is Public Interest Protected, in World Health Report 2. Health system: Improving Performance, Murray CJL. AcharyaAk, Understanding DALYs. J Health Econ 997;6: Naghavi M, Abolhassani F, Moradi Lake M, Jafari N, Shoaaee SH, Vosughi S, et al. National burden of disease Studies: A Practical guide for National and Provincial Level. Ministry of Heath, Treatment and Medical education, Tehran Murray CJL, Lopez AD. The Global burden of disease: A Comprehensive Assessment of Mortality and disability form diseases, injuries and risk factors in 99 and projected to Global burden of disease and Injury Series. Gold man L, Austell D. Cecil Textbook of Medicine, 22th Edition, WB Saunders Company: USA, 23, Harvard University Press. 6. Naghavi M, Abolhassani F. Moradi Lake M, Disease burden in three Provinces of IRAN, Western Azerbaijan, Booshehr and Charmahale Bakhtiari 2. Ministry of Health, Treatment and Medical education, Tehran Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 28 v.2, Cancer incidence and Mortality Worldwide: IARC Cancer Base No.. Lyon, France: International Agency for Research on Cancer; (2)). Available from: [Last accessed on 22 July 22]. 8. Foroutan M, Rahimi N, Tabatabaeifar M, Darvishi M, Hashemi M, Hossein-Panah F, Zali MR. Clinical features of

8 /8 colorectal cancer in Iran: a 5-year review J Dig Dis. 28 4: Ansari R, Mahdavinia M, Sadjadi A, Nouraie M, Kamangar F, Bishehsari F, Fakheri H, Semnani S, Arshi S, Zahedi MJ, Darvish-Moghadam S, Mansour-Ghanaei F, Mosavi A, Malekzadeh R. Incidence and age distribution of colorectal cancer in Iran: results of a population-based cancer registry, Cancer Letter. 26 Aug 8; 24: Epub 25.. Isabelle Soerjomataram, Melissa S. Y. Thong,Majid Ezzati, Elizabeth B. Lamont,Wilma J. Nusselder, Lonneke V. van de Poll-Franse, Most colorectal cancer survivors live a large proportion of their remaining life in good health, Cancer Causes Control 22, 23: Ardeshir Khosravi, Richard Taylor, Mohsen Naghavi & Alan D Lopeza, Mortality in the Islamic Republic of Iran, , Bulletin of the World Health Organization 27; 85: Rashidian A, KhosraviA, Arab M, Beheshtian M, Khabiri R, Karimi A. I.R. Iran Multiple-Indicator Demographic and Health Survey 2. Deputy for Health Ministry of Health and Medical Education. 3. Ministry of Health, Treatment and Medical education, National burden of disease and injuries in IRAN, 27, Tehran Stouthard MEA, Essink -Bot ML, Bonsel GJ, on behalf of the Dutch Disability Weights Group. Disability weights for diseases: a modified protocol and results for a Western European region. Eur J Public Health. 2; : Moradi A, Khayamzadeh M, Guya MM, Mirzaei HR, Salmanian R, Rakhsha A, Akbari ME. Survival of colorectal cancer in Iran. Asian Pacific Journal of Cancer Prevention. 29 Oct-Dec; : Moghimi-Dehkordi B, Safaee A, Zali MR. Comparison of colorectal and gastric cancer: survival and prognostic factors. Saudi Journal of Gastroenterology. 29 Jan; 5: Hoseini Nasab A, Modir A, Shiryazdi M. Survival of colorectal cancer patients in Yazd. Journal of Shahid Sadoghi University of Medical Sciences 2; 9(4); Asghari-Jafarabadi M, Hajizadeh E, Kazemnejad A, Fatemi SR. Recognition of the factors affecting survival in colon and rectal cancer patients referred to RCGLD center of Shahid Beheshti University of Medical Sciences: accelerated failure time parametric survival analysis with frailty. Journal of Sharekord University of Medical Sciences 2; 22(2): Aryaie M, A survey of survival rate in colorectal cancer patients in Golestan province,2, submitted in partial fulfillment of the requirements for degree of master of science. 2. Centers for Disease Control and Prevention. (29). United States cancer statistics. From the centers for disease control and prevention website: 2. Mehrkhani F, Nasiri S, Donboli K, Meysami A, Hedayat A.(29). Prognostic factors in survival of colorectal cancer patients after surgery. Colorectal Dis 29; : Ghazali AK, Musa KI, Naing NN, Mahmood Z. Prognostic factors in patients with colorectal cancer at Hospital University Sains Malaysia. Asian J Surg; 2; 33: Chu, D. Z. (27). Cancer recurrence and survival associated with dietary patterns in stage III colon cancer. Jama, 298(9), 2263; author reply Benson AB, Schrag D, Somer eld MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clinic Oncology 24; 22: Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer. N Engl J Med 24; 35: Hawk ET, Umar A, Viner JL. Colorectal Cancer Chemoprevention: an overview of the science. Gastroenterology 24; 26: Reichmann C, Sargent DJ. New treatment options for colorectal cancer. N Engl J Med 24; 35: Van Custom, Dicato M, Wills J, et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, Eur J Cancer 22;38: Liobera J, Esteva M, et al.(2). Terminal cancer: duration and prediction of survival time. European Journal ofcancer,36, Morris JN, Suissa S, Sherwood S, Wright SM, Greer D. Last days: a study of the quality of life of terminally ill patients. J Chron Dis,986,39, Vigano A, Bruera E, Suarez-Almanzor ME. Terminal cancer syndrome: myth or reality? J Palliat Care 999, 5, Coale A, Demeny P, Vaughan B. Regional model life tables and stable populations. 2nd ed. New York (NY): Academic Press; World Health Organization. The global burden of disease: 24 update. Geneva, World Health Organization, 28. Available at National report of cancer registration in Iran. Ministry of health, treatment and Medical education, Tehran Safaei A, Moghimi Dehkordy B, Fatemi SR, Zali MR. Epidemiology of colorectal cancer: Study the recorded cases in Tbib-e-Shargh J. 27; 9: Emami MH, Fatemi AM, Farajzadegan Z, Movahed Abtahi SM. Epidemiology of colorectal cancer in Isfahan. Govaresh. 25; : 34-9.

9 9/ 387 Iranian Journal of Epidemiology 24; 9(4): -9. Original Article Estimation of the Attributable Burden of Colorectal Cancer in Iran in 28 Mahmoudlou A, Yavari P 2, Abolhasani F 3, Khosravi A 4, Ramazani R 5 - MSc Student of Epidemiology, School of public health, Shahid Beheshti University of Medical Science, Tehran, Iran Shahid Beheshti University of Medical Science, Tehran, Iran 2- Professor of Epidemiology 3- Associated professor in Internal diseases, Tehran University of Medical Science, Tehran, Iran 4- PhD of Population Health, Ministry of Health and Medical Education, Tehran 5- Specialty in Internal disease, Ministry of Health and Medical Education, The Office of Cancer Registry, Tehran, Iran Corresponding author: Yavari P, p.yavari-gir@sbmu.ac.ir Background and Objectives: Colorectal cancer, as the third common cancer, is one of the main health problems in Iran. We assessed the burden of colorectal cancer, as one of the high-priority indices, in this cross-sectional study in Iran in 28. Methods: CANMOD software was used for calculation. The input data included the population of Iran, all-cause and colorectal cancer mortality rates, and incidence rate of colorectal cancer, which were all obtained from the Iran Statistic Center, Mortality Registry System, and Cancer Registry System. Results: The total burden of colorectal cancer according to DALY in Iran in 28 was years in the total population. Years of lost life (YLL) amongst males and females were and 9887 years, respectively. Years lived with disability (YLD) were 3473 and 279 years for males and females, respectively. The burden of colorectal cancer per population was 75.4 years for males and 65.7 years for females. The peak age of colorectal cancer burden rate was in the age group years. Conclusion: The burden of the colorectal cancer in Iran has increased compared to the last study (23) which is due to the increase in its incidence and the related mortality during this period. Due to the possibility of prevention and effective intervention, this cancer should be a priority in the health care system. However, the final judgment should be made after calculation of the burden of other cancers, diseases, and damages at the country level and their respective rankings. Keywords: Colorectal cancer, DALY, Disease burden